Actavis completes $71bn acquisition of Allergan
Dublin-based pharmaceutical company Actavis has completed its acquisition of Allergan for $71 billion.
In a statement today (March 17), Actavis said that the deal creates one of the world’s ten largest pharma companies by sales revenue.
Allergan makes products including Botox and Juvéderm.
Brent Saunders, chief executive of Actavis, said he believes the new company (known as Actavis) has many first-to-file generic opportunities in the US and that it now has more than 1,000 marketing authorisations worldwide.
Saunders added: “Anchored by world-renowned brand franchises, a leading global generics business, a premier pharma development pipeline and an experienced management team committed to maintaining highly efficient operations across the organisation, we are creating an unrivalled foundation for long-term growth.”
The European Commission confirmed the transaction’s closure yesterday (March 16). Details of the acquisition were first announced in November last year.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk